Verrica Pharmaceuticals

Update in progress

VRCA (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Verrica Pharmaceuticals is a dermatology-focused company developing and commercializing treatments for skin diseases in the United States. Its lead product, YCANTH (VP-102), is a GMP-formulated cantharidin drug-device combo for molluscum contagiosum in adults and children and for common warts. VP-315 is an injectable oncolytic peptide in Phase II for dermatologic cancers, including basal cell carcinoma. Partners include Torii (Japan) and Lytix Biopharma for VP-315. Founded 2013, based in West Chester, PA.

Company score

Sentiment: -0.21; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.12; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.43; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.13; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive